Adverum Biotechnologies, Inc.
ADVM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -72.2% | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13,550.6% | -3,424.9% | – | -1,886.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13,092.7% | -3,392.1% | – | -1,940.5% |
| EPS Diluted | -6.62 | -2.02 | -2.67 | -1.48 |
| % Growth | -227.7% | 24.3% | -80.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |